Eli Lilly & annual operating income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eli Lilly & Operating Income Growth & History (LLY)
Eli Lilly &'s operating income was $26.30B for fiscal 2025.
View full Eli Lilly & company overviewEli Lilly & annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $26.30B | $13.40B | +103.91% |
| 2024 | 2024-12-31 | $12.90B | $6.44B | +99.77% |
| 2023 | 2023-12-31 | $6.46B | −$670.3M | −9.40% |
| 2022 | 2022-12-31 | $7.13B | $770.2M | +12.12% |
| 2021 | 2021-12-31 | $6.36B | $299.1M | +4.94% |
| 2020 | 2020-12-31 | $6.06B | $1.08B | +21.79% |
| 2019 | 2019-12-31 | $4.97B | $1.44B | +40.74% |
| 2018 | 2018-12-31 | $3.53B | $1.53B | +76.43% |
| 2017 | 2017-12-31 | $2.00B | −$1.26B | −38.57% |
| 2016 | 2016-12-31 | $3.26B | $571.8M | +21.26% |
| 2015 | 2015-12-31 | $2.69B | $29.6M | +1.11% |
| 2014 | 2014-12-31 | $2.66B | −$2.71B | −50.47% |
| 2013 | 2013-12-31 | $5.37B | $636.2M | +13.44% |
| 2012 | 2012-12-31 | $4.73B | −$794.3M | −14.37% |
| 2011 | 2011-12-31 | $5.53B | −$1.00B | −15.34% |
| 2010 | 2010-12-31 | $6.53B | $942.9M | +16.88% |
| 2009 | 2009-12-31 | $5.59B | $6.92B | — |
| 2008 | 2008-12-31 | −$1.33B | — | — |
Eli Lilly & quarterly operating income
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.98B | $2.11B | +30.74% |
| Q1 2026 | 2026-03-31 | $8.91B | $5.22B | +141.27% |
| Q4 2025 | 2025-12-31 | $8.37B | $3.23B | +62.65% |
| Q3 2025 | 2025-09-30 | $7.37B | $5.84B | +382.54% |
| Q2 2025 | 2025-06-30 | $6.87B | $3.15B | +84.86% |
| Q1 2025 | 2025-03-31 | $3.69B | $1.19B | +47.27% |
| Q4 2024 | 2024-12-31 | $5.15B | $2.76B | +115.71% |
| Q3 2024 | 2024-09-30 | $1.53B | $1.08B | +238.90% |
| Q2 2024 | 2024-06-30 | $3.71B | $1.59B | +74.76% |
| Q1 2024 | 2024-03-31 | $2.51B | $1.01B | +67.94% |
| Q4 2023 | 2023-12-31 | $2.39B | $550.5M | +29.98% |
| Q3 2023 | 2023-09-30 | $450.4M | −$1.23B | −73.13% |
| Q2 2023 | 2023-06-30 | $2.13B | $915.6M | +75.66% |
| Q1 2023 | 2023-03-31 | $1.49B | −$910.3M | −37.86% |
| Q4 2022 | 2022-12-31 | $1.84B | −$80.8M | −4.21% |
| Q3 2022 | 2022-09-30 | $1.68B | −$204.7M | −10.88% |
| Q2 2022 | 2022-06-30 | $1.21B | −$193.3M | −13.77% |
| Q1 2022 | 2022-03-31 | $2.40B | $1.25B | +108.11% |
| Q4 2021 | 2021-12-31 | $1.92B | −$74.9M | −3.76% |
| Q3 2021 | 2021-09-30 | $1.88B | $602.9M | +47.16% |
| Q2 2021 | 2021-06-30 | $1.40B | $206.6M | +17.26% |
| Q1 2021 | 2021-03-31 | $1.16B | −$435.5M | −27.38% |
| Q4 2020 | 2020-12-31 | $1.99B | $591.9M | +42.27% |
| Q3 2020 | 2020-09-30 | $1.28B | −$152.4M | −10.65% |
| Q2 2020 | 2020-06-30 | $1.20B | −$301.5M | −20.12% |
| Q1 2020 | 2020-03-31 | $1.59B | $945.7M | +146.60% |
| Q4 2019 | 2019-12-31 | $1.40B | $500.0M | +55.54% |
| Q3 2019 | 2019-09-30 | $1.43B | $87.7M | +6.53% |
| Q2 2019 | 2019-06-30 | $1.50B | $1.50B | — |
| Q1 2019 | 2019-03-31 | $645.1M | −$651.1M | −50.23% |
| Q4 2018 | 2018-12-31 | $900.2M | — | — |
| Q3 2018 | 2018-09-30 | $1.34B | $801.3M | +147.92% |
| Q2 2018 | 2018-06-30 | −$4.9M | −$1.21B | — |
| Q1 2018 | 2018-03-31 | $1.30B | $1.31B | — |
| Q3 2017 | 2017-09-30 | $541.7M | −$401.8M | −42.59% |
| Q2 2017 | 2017-06-30 | $1.20B | $276.8M | +29.98% |
| Q1 2017 | 2017-03-31 | −$17.1M | −$732.9M | — |
| Q4 2016 | 2016-12-31 | $678.6M | $278.7M | +69.69% |
| Q3 2016 | 2016-09-30 | $943.5M | −$17.8M | −1.85% |
| Q2 2016 | 2016-06-30 | $923.3M | $120.3M | +14.98% |
| Q1 2016 | 2016-03-31 | $715.8M | $190.6M | +36.29% |
| Q4 2015 | 2015-12-31 | $399.9M | $23.5M | +6.24% |
| Q3 2015 | 2015-09-30 | $961.3M | $399.3M | +71.05% |
| Q2 2015 | 2015-06-30 | $803.0M | −$83.6M | −9.43% |
| Q1 2015 | 2015-03-31 | $525.2M | −$309.6M | −37.09% |
| Q4 2014 | 2014-12-31 | $376.4M | −$524.4M | −58.21% |
| Q3 2014 | 2014-09-30 | $562.0M | −$982.7M | −63.62% |
| Q2 2014 | 2014-06-30 | $886.6M | −$616.4M | −41.01% |
| Q1 2014 | 2014-03-31 | $834.8M | −$587.1M | −41.29% |
| Q4 2013 | 2013-12-31 | $900.8M | −$163.6M | −15.37% |
| Q3 2013 | 2013-09-30 | $1.54B | $458.5M | +42.21% |
| Q2 2013 | 2013-06-30 | $1.50B | $300.8M | +25.02% |
| Q1 2013 | 2013-03-31 | $1.42B | $40.6M | +2.94% |
| Q4 2012 | 2012-12-31 | $1.06B | −$4.2M | −0.39% |
| Q3 2012 | 2012-09-30 | $1.09B | −$499.7M | −31.51% |
| Q2 2012 | 2012-06-30 | $1.20B | −$386.7M | −24.34% |
| Q1 2012 | 2012-03-31 | $1.38B | $96.2M | +7.49% |
| Q4 2011 | 2011-12-31 | $1.07B | −$380.4M | −26.25% |
| Q3 2011 | 2011-09-30 | $1.59B | −$107.1M | −6.33% |
| Q2 2011 | 2011-06-30 | $1.59B | −$166.0M | −9.46% |
| Q1 2011 | 2011-03-31 | $1.29B | −$348.2M | −21.32% |
| Q4 2010 | 2010-12-31 | $1.45B | — | — |
| Q3 2010 | 2010-09-30 | $1.69B | $556.6M | +48.98% |
| Q2 2010 | 2010-06-30 | $1.75B | $263.1M | +17.64% |
| Q1 2010 | 2010-03-31 | $1.63B | — | — |
| Q3 2009 | 2009-09-30 | $1.14B | — | — |
| Q2 2009 | 2009-06-30 | $1.49B | — | — |
Eli Lilly & operating income trends
Over the last five fiscal years, Eli Lilly &'s operating income increased from $6.06B to $26.30B, a change of $20.24B. The latest reported quarter, Q2 2026, shows $8.98B.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eli Lilly & source filings ↗